ALLUVI: A DEEP ANALYSIS INTO RETATRUTIDE'S POSSIBILITY

Alluvi, initially dubbed LY3414901, represents a significant advancement in obesity management. This twin -action glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) target agonist exhibits remarkable impact in early clinical data, with considerable weight loss